All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
New drug application for duvelisib accepted and granted priority review by FDA
It was announced in a press release that the US Food and Drug Administration has accepted a new drug application for duvelisib and granted a priority review on 09 April 2018.
Duvelisib is the first oral dual inhibitor of phosphoinositide-3-kinase-delta (PI3K-δ) and PI3K-γ being developed by Verastem. The company hopes to see full approval of duvelisib for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and accelerated approval for the treatment of R/R follicular lymphoma.
Robert Forrester, President and Chief Executive Officer of Verastem commented that the priority review, "speaks to the unmet need in relapsed and refractory CLL and FL and the urgency to identify effective therapies to treat these patients". The FDA target action date has been established as 05 October 2018.
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?